Rocket製藥 RCKT 深 滬
已收盤 06-18 16:00:00 美东时间
3.35
+0.190
+6.01%
華盛通- 最 高3.38
- 今 開3.28
- 成交量 1128.72万股
- 最 低 3.19
- 昨 收 3.16
- 總市值 3.66亿
- 52周最高 5.45
- 市盈率 靜 --
- 換手率 10.34%
- 52周最低 2.40
- 委 比 -97.04%
- 總股本 1.09亿
- 歷史最高 67.48
- 量 比 4.04
- 振 幅 6.01%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rocket Pharma updates cash position after selling priority review voucher
Rocket Pharmaceuticals (RCKT) on Friday disclosed more than $320M in cash, cash equivalents, and investments pro forma after completing the previously disclosed sale of its rare pediatric disease prio...
06-12 19:31
Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M
The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency. As previously reported, before the PRV...
06-12 19:02
Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million
Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 180 million. The voucher was awarded in March 2026 tied to the FDA approval of KRESLADI
06-12 19:00
Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share
05-08 04:24
US FDA's accelerated approval for drugs needs more transparency, says research firm
US FDA's accelerated approval for drugs needs more transparency, says research firm By Sneha S K April 16 (Reuters) - The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical and Econo
04-16 20:00
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 27 (Reuters) - Wall Street's main indexes were on track to open lower
03-27 21:15
Why Is Rocket Pharma Stock Soaring Friday?
Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash runway and support growth plans.
03-27 21:13
美国FDA批准首款致命儿童罕见病疗法，火箭制药股价上涨
美国食品药品监督管理局（FDA）批准火箭制药（Rocket Pharmaceuticals）一款针对儿童罕见且通常致命的免疫缺陷疾病的基因疗法后，该公司股价...
03-27 20:06
